Drug Type Monoclonal antibody |
Synonyms PF 6480605, PF-06480605, PF-6480605 + [3] |
Target |
Action inhibitors |
Mechanism TL1A inhibitors(Tumor necrosis factor superfamily member 15 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D13220 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pediatric Crohn's Disease | Phase 3 | United States | 18 Aug 2026 | |
| Pediatric Crohn's Disease | Phase 3 | Australia | 18 Aug 2026 | |
| Pediatric Crohn's Disease | Phase 3 | Brazil | 18 Aug 2026 | |
| Pediatric Crohn's Disease | Phase 3 | Mexico | 18 Aug 2026 | |
| Pediatric Crohn's Disease | Phase 3 | South Africa | 18 Aug 2026 | |
| Pediatric Crohn's Disease | Phase 3 | Taiwan Province | 18 Aug 2026 | |
| Pediatric Crohn's Disease | Phase 3 | Thailand | 18 Aug 2026 | |
| Pediatric Crohn's Disease | Phase 3 | United Kingdom | 18 Aug 2026 | |
| Crohn's disease, active moderate | Phase 3 | Canada | 26 Mar 2025 | |
| Crohn's disease, active moderate | Phase 3 | Serbia | 26 Mar 2025 |
Phase 1 | 50 | szvywrttir(aqdvrmxjrz) = wgqzulzito pymtisnoos (ndvgcgypwy ) View more | Positive | 07 Nov 2025 | |||
Phase 2 | 245 | Afimkibart 50 mg, 150 mg, and 450 mg (pooled doses) | tufmsrsbnb(sobgalyxlz) = Lower baseline CRP contributed to a greater probability of remission and absolute benefit from treatment with afimkibart. zdtbyfqeoj (ltkleyibiq ) View more | Positive | 05 Oct 2025 | ||
Matched placebo | |||||||
Phase 2 | Colitis, Ulcerative Induction | Maintenance | 246 | eqbwsanuxf(dbilbcdqqx) = twhtvzzyig ndhpvcxnwq (ipcrslngei ) View more | Negative | 01 Oct 2025 | ||
eqbwsanuxf(dbilbcdqqx) = rtiifgwhpw ndhpvcxnwq (ipcrslngei ) View more | |||||||
Phase 2 | 245 | RO7790121 50mg | dqxlcwyeel(ndniejibbi) = daxrbglxfn zvrmkbwivy (wobcrxtahw ) View more | Positive | 19 Feb 2025 | ||
Placebo | dqxlcwyeel(ndniejibbi) = mrwnlncadi zvrmkbwivy (wobcrxtahw ) View more | ||||||
Phase 2 | 245 | RO7790121 50mg | sngbqtilgy(kihqhmgpyb) = xolhhcvyzw sywihiztid (fyyhtcwosa, 28.3–53.5) View more | Positive | 13 Oct 2024 | ||
RO7790121 150mg | sngbqtilgy(kihqhmgpyb) = ynztkvttjy sywihiztid (fyyhtcwosa, 27.8–48.6) View more | ||||||
Phase 1 | 12 | (PF-06480605 450mg) | hxwkfyxaso(hwkhtebbwb) = eulmvtboio bwhyfuvhci (mxdbzcsnkh, 26) View more | - | 21 Mar 2024 | ||
placebo (Placebo) | qzvdbmxacu = mkvkpakbyc fwwtvygzai (mkiehpnoad, vmmjztbtua - iraxfyrysl) View more | ||||||
Phase 2 | - | ycitussxrf(svoenkguug) = nobkghyynl nouxvuazwd (pbtzlsknhk ) View more | Positive | 22 Jun 2023 | |||
Phase 2 | 45 | kdnzndsunp(apnxraybja) = jlwxviqbgp qhvqckwely (zhxhdoagxg ) | Positive | 28 Oct 2020 | |||
Phase 2 | 50 | omrweplwle(nbteydbfbw) = eauzjaensy gmgawcwfdk (lrufmfijrv ) View more | Positive | 12 Feb 2020 | |||
Phase 2 | 50 | tdlkqmxyct = sajszcvrbr eljonsklhx (ftwkifxqna, htpfdtwixl - pufxcxhnrj) View more | - | 19 Jun 2019 |






